Quantum Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hugues Meyrath
- Full Time Employees
- 490
- Sector
- Technology
- Industry
- Computer Hardware
- Address
- 10770 East Briarwood Avenue Centennial CA United States of America 80112
- IPO Date
- Aug 2, 1999
- CIK
- 0000709283
- Website
- quantum.com
- Similar Companies
- Business
- Quantum Corporation (Nasdaq: QMCO), founded in 1980 and headquartered in Centennial, Colorado, develops and markets end-to-end data management solutions for storing, protecting, managing, and analyzing unstructured data including video and AI workloads; its core products and services encompass high-performance platforms such as Myriad all-flash file and object storage, StorNext file system, and Unified Surveillance Platform; data protection and archiving offerings including ActiveScale object storage, DXi backup appliances with deduplication, and Scalar tape storage; as well as AI-enabled workflow management via CatDV media asset management and cloud-based analytics; the company serves enterprises, government agencies, media production, surveillance, healthcare, and research sectors across the Americas, Europe, Middle East, Africa, Asia-Pacific, and recently expanded distribution networks in China, India, and ASEAN regions. In recent developments, Quantum enters a definitive agreement in September 2025 with Dialectic Capital Management and other lenders to restructure approximately $52 million in term debt into senior secured convertible notes, enhancing financial flexibility, eliminating leverage covenants, and issuing warrants for 2.653 million shares while retaining up to $15 million in proceeds for working capital; the company rebuilds its board and executive team including CEO Hugues Meyrath to drive operational transformation and revenue growth; it launches Scalar i3 tape storage in December 2025 doubling capacity with new iSCSI Ethernet bridge connectivity; and introduces ActiveScale ranged restore for faster Glacier-class archives alongside MyQuantum unified data platform to power AI data lakes and cyber-resilient backups.
QTREX's Patent-Pending Technology Achieves First Direct Conversion of 3D-Printed Insulation into Graphene-Like Carbon to Protect Quantum Processors
3 Quantum Computing Stocks With the Most Upside in August
D-Wave Quantum vs. Microsoft: Which Is the Better Quantum Computing Stock to Own for the Next 5 Years?
Quantum Stocks Fall Tuesday as Rates Force Rotation: IonQ Down 6%, D-Wave Drops 6%, Rigetti Falls 5%
Infleqtion to Test Quantum Sensing in Colorado to Advance U.S. Critical Minerals Security
U.S.-China 2026 Tech Race: 2 AI Stocks & 2 Quantum Stocks to Watch
1 Quantum Stock Near 52-Week Lows With Nvidia Partnership Backing Is Poised to Rebound
Infleqtion Opens Colorado Quantum Innovation Center, Anchoring "America's Quantum Peak"
Quantinuum: Pioneering The Future Of Quantum Computing
ASP Isotopes Announces Quantum Leap Energy is Evaluating Metal Conversion Opportunities in Namibia
Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
QSE Introduces QSim, a New Product for Planning Post-Quantum Migration
D-Wave Technology Drives NTT DOCOMO's Second Production Quantum Application in Network Operations
Two Quantum Computing Stocks Are Starting to Pull Ahead of the Pack
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
Quantum Cyber to Participate in Invitation-Only 1640 Society Hamptons Family Office Wealth Forum 2026
3 Quantum Computing Stocks for Aggressive Investors in August
Horizon Quantum Builds Software Stack for the Race to Practical Quantum Computing
BTQ Technologies Provides Q2 2026 Corporate Update Highlighting Commercial Progress Across Trusted Quantum Technologies Platform
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial